Focus keyword: non small cell lung cancer
SEO Title (60 chars):
Non Small Cell Lung Cancer: 3 Critical Zykadia Approval Facts
Meta Description (152 chars):
The European Commission approved Zykadia for ALK positive non small cell lung cancer, offering a critical new targeted therapy option after crizotinib failure.
URL Slug:
non-small-cell-lung-cancer-zykadia-approval
Image Alt Text:
prescription capsules representing targeted therapy for non small cell lung cancer
Non small cell lung cancer is the most common form of lung cancer, accounting for 85 to 90 percent of all cases in a disease that kills more people worldwide than any other cancer. Each year, approximately 1.6 million people are diagnosed with lung cancer globally. Among those with non small cell lung cancer, two to seven percent carry a rearrangement of the anaplastic lymphoma kinase gene, known as ALK positive disease, which drives cancer cell growth and can be identified through molecular testing of the tumor. The European Commission has now approved Zykadia, generically known as ceritinib, as a targeted treatment option for adult patients with ALK positive advanced non small cell lung cancer who have previously been treated with crizotinib.
Why ALK Positive Non Small Cell Lung Cancer Requires Targeted Treatment
ALK positive non small cell lung cancer is defined by a specific genetic rearrangement that functions as a primary driver of tumor growth. This genetic characteristic makes it amenable to treatment with ALK inhibitors, drugs designed to block the activity of the abnormal ALK protein. Crizotinib was the first approved ALK inhibitor and became the established first line treatment for this patient population.
However, disease progression following crizotinib treatment is common and often inevitable. When that progression occurs, patients with ALK positive non small cell lung cancer have had very few targeted options available. The approval of Zykadia directly addresses this unmet need by providing a second line therapy that specifically targets the genetic driver of the disease rather than relying on broadly toxic chemotherapy approaches.
The Clinical Evidence Behind the Non Small Cell Lung Cancer Approval
The European approval of Zykadia is supported by data from two global, multicenter, open label, single arm studies known as ASCEND 1 and ASCEND 2. Data from ASCEND 1 demonstrated that patients with ALK positive non small cell lung cancer who received Zykadia at 750 mg daily after prior treatment with chemotherapy followed by an ALK inhibitor achieved an overall response rate of 56.4 percent. These results were considered clinically meaningful for a patient population that had exhausted prior treatment options.
The EU approval followed a positive opinion adopted by the Committee for Medicinal Products for Human Use in February 2015 and applied to all 28 EU member states as well as Iceland, Norway, and Liechtenstein. At the time of approval, Zykadia was already approved in the United States and other countries across North America, South America, Central America, and Asia, with additional regulatory reviews underway worldwide.
What the Zykadia Approval Means for Precision Oncology
The approval of Zykadia represents a meaningful advance in precision oncology, the approach to cancer treatment that matches therapies to the specific genetic and molecular characteristics of a patient’s tumor rather than treating all cancers of a given tissue type with the same regimen. For patients with ALK positive non small cell lung cancer, molecular testing at diagnosis is essential to determining treatment strategy, and targeted therapies like Zykadia are only appropriate for those whose tumors carry the ALK rearrangement.
As Stefania Vallone of Lung Cancer Europe noted, molecular testing for genetic drivers plays a critical role in treatment decisions, particularly when patients experience disease progression after initial therapy. The availability of a second ALK targeted option gives clinicians and patients a meaningful tool for responding to crizotinib resistance without abandoning the precision oncology framework.
According to Bruno Strigini, President of Novartis Oncology, the approval reflects the company’s continued commitment to developing treatments that target specific genetic characteristics of cancer, a direction that is reshaping how lung cancer and many other malignancies are managed.
The Future of Treatment for ALK Positive Non Small Cell Lung Cancer
The approval of Zykadia in the EU underscores that resistance to initial ALK inhibitor therapy does not mean the end of targeted treatment for ALK positive non small cell lung cancer patients. As additional next generation ALK inhibitors continue to advance through clinical development, the treatment landscape for this molecular subtype is expanding.
Clinical research remains essential to understanding resistance mechanisms, optimizing treatment sequencing, and identifying which patients benefit most from which therapies at each stage of disease. Participation in clinical trials offers patients with ALK positive non small cell lung cancer access to emerging therapies while contributing to the evidence base that will guide future treatment guidelines.
To read more about oncology research, visit the FOMAT blog. FOMAT conducts oncology clinical trials including lung cancer studies at sites across the United States. To learn more about active studies, visit FOMAT’s patient studies page.
For the full source, see the original article at DDDmag.com.